Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment[3]. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
MSCs as Essential Raw Materials for Regenerative Medicine Products
MSCs are essential raw materials for many regenerative medicine products, including cell-based therapies, engineered tissues, cosmeceutical preparations, exosome products, and cultured meat. As of today, ClinicalTrials.gov lists at least 2,232 registered clinical trials involving MSCs, targeting a variety of indications ranging from graft vs. host disease (GvHD) to macular degeneration to osteoarthritis. Although ten MSC-based therapeutics have been approved for marketing in other parts of the world, the U.S. FDA is yet to approve an MSC product. Nonetheless, given their therapeutic potential for treating many indications and usage across a variety of applications, researchers believe that MSCs will support many important regenerative medicine advances. [Read more…]
Gameto Secures $44M Series C to Advance Fertilo as First iPSC-Derived Reproductive Therapy to Reach Phase 3 in the U.S.
- As birth rates decline and USÂ IVF access falls further behind, Gameto recruits first Phase 3 patients for cutting-edge biotechnology to reignite reproductive health possibilities
- Company’s $127 million in total funding represents one of the largest investment in reproductive US biopharma sector to date
AUSTIN, Texas, Aug. 12, 2025 – Gameto, a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health, today announced the completion of a $44 million Series C financing round led by Overwater Ventures, with participation from Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners, Portfolia, and additional investors. [Read more…]
Mirugen Secures A$4.5M to Advance In Vivo Cell (Re)programming, Positioning Itself as a Pioneer in the Field
Mirugen has built a strong syndicate of Australia’s leading life science and deep tech investors to drive its next phase of growth, appointing seasoned biotech entrepreneur Charlotte Casebourne Stock as Executive Chair and Acting CEO to guide the company through key development milestones.
Stem Cell Treatments For Macular Degeneration
Macular degeneration is a crushing condition, leading to loss of visual acuity, and in some cases, eventual blindness. Even those who don’t experience total eyesight loss suffer a frustrating degradation of central vision, which makes driving, using the computer or other devices, recognizing faces, reading and many other activities nearly impossible to do. However, recent advancements in stem cell treatments for macular degeneration are providing a beacon of hope to many. [Read more…]
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- …
- 338
- Next Page »